Every 10-Q that Natera Inc (NTRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NTRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTRA filings page.
Natera, Inc. reported strong top-line growth in Q2 2026, with total revenues of 752,750 versus 546,600 a year earlier (three-month periods, in thousands of dollars). For the first half of 2026, revenue rose to 1,449,394 from 1,048,431, while net loss narrowed to 66,969 for the quarter and 152,060 year-to-date.
Natera held 1,091,502 in cash, cash equivalents and restricted cash at June 30, 2026, generated 94,964 of operating cash flow in the first half, and had 80,291 of short‑term debt under an 80.3 million Credit Line (all in thousands). Total assets were 2,657,497 and stockholders’ equity 1,821,499, and management believes existing cash will fund operations for at least 12 months.
The results reflect integration of the 424.5 million acquisition of Foresight Diagnostics, which added 141.1 million of goodwill and significant developed technology intangibles, along with 120,505 (thousands) of contingent consideration. Legal matters remain a notable risk, including approximately 33.2 million accrued for legal contingencies and a jury award of 57.0 million in a Ravgen patent case that Natera is appealing.
Natera, Inc. reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Total revenues rose to $696.6 million from $501.8 million a year earlier, driven mainly by product revenues of $693.9 million.
The company recorded a net loss of $85.1 million, compared with a loss of $66.9 million in the prior-year quarter, as research and development plus selling, general and administrative expenses expanded. Basic and diluted net loss per share was $0.60 versus $0.50 a year ago.
Natera ended the period with $1.09 billion in cash, cash equivalents and restricted cash and generated $40.2 million of cash from operating activities. Total assets were $2.61 billion, including goodwill and intangible assets largely from the Foresight Diagnostics acquisition, while stockholders’ equity stood at $1.77 billion.
Natera, Inc. reported strong Q3 2025 topline growth alongside wider losses. Total revenues reached $592.2 million, up from $439.8 million a year ago, driven mainly by product revenues of $590.2 million. The company posted a net loss of $87.5 million, compared with a $31.6 million loss in Q3 2024, and a basic and diluted loss per share of $0.64 versus $0.26.
Operating expenses increased as Natera continued investing in its platform: research and development was $173.4 million and selling, general and administrative was $308.5 million. Revenue in the quarter included a $55.1 million net increase from changes in estimates for tests delivered in prior periods that were fully collected, which reduced loss per share by $0.40, and a $2.9 million revenue reduction from estimated insurance refunds, which increased loss per share by $0.02.
Liquidity remained solid. Cash, cash equivalents and restricted cash were $1.04 billion at September 30, 2025. Year‑to‑date operating cash flow was $141.4 million. The balance sheet shows $80.3 million outstanding on the Credit Line and $1.25 billion in stockholders’ equity. As context, common shares outstanding were 138,014,465 as of October 31, 2025.